NGM Bio to Participate in the Cowen 42nd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals (NGM) announces CEO David J. Woodhouse will participate in the Cowen 42nd Annual Health Care Conference on March 7, at 10:30 am ET. The presentation will focus on the company's oncology portfolio and provide a comprehensive business update. Interested parties can watch a live webcast on NGM's website, which will be available for replay for 30 days post-event. NGM is dedicated to developing transformative therapies targeting cancer, retinal diseases, and metabolic disorders.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in the Cowen 42nd Annual Health Care Conference as part of the Novel Immuno-oncology (IO) Panel and will provide an overview of the company and a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Monday, March 7, at 10:30 am ET.
A live webcast of the presentation will be available under the Investors and Media section of NGM Bio’s website at https://ir.ngmbio.com/events-presentations. A replay of each presentation will be archived on NGM Bio’s site for 30 days following the event.
About NGM Biopharmaceuticals, Inc.
NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, with a disease-agnostic mindset, always led by biology and motivated by unmet patient need. Today, the company has seven disclosed programs, including four in Phase 2 or 2b studies, across three therapeutic areas: cancer, retinal diseases and liver and metabolic diseases. Visit us at www.ngmbio.com for more information.
| Investor Contact: Brian Schoelkopf ir@ngmbio.com | Media Contact: media@ngmbio.com |
FAQ
What event will NGM participate in on March 7, 2022?
Who will represent NGM at the Cowen Conference?
What will NGM discuss during the Cowen Conference?
How can I watch NGM's presentation at the Cowen Conference?
How long will the webcast replay be available after the event?
What therapeutic areas does NGM focus on?
How many programs are currently in NGM's pipeline?
